processes have been long established for conditions such as blood loss, in the last 2 decades, it has become clear that even vascular and myocardial injury is followed by regeneration that is mediated by circulating and resident vascular progenitors. When the regenerative potential is insufficient or deficient, then vascular injury progresses. We and others have shown that circulating progenitor cells (CPCs) can be accurately phenotyped in humans. CPCs have been characterized as CD34-expressing mononuclear cells that possess the potential to differentiate into hematopoietic, endothelial, and nonhematopoietic (mesenchymal, lacking CD45 expression) lineages and contribute to vascular and myocardial regeneration. [3] [4] [5] [6] [7] CD133 is a 5-transmembrane antigen of primitive stem cells which is lost during maturation, and dual expression of these markers (CD34+/CD133+) can detect a PCenriched subpopulation. 8, 9 Coexpression of VEGFR2 (vascular endothelial growth factor receptor-2) seems to identify a scarcer subpopulation of CPCs further enriched for endothelial progenitors. 10, 11 Coexpression of CXCR4 (chemokine [C-X-C motif] receptor 4) permits homing of CPCs to stromal-derived factor-rich hypoxic milieu and further characterizes the subpopulation of CD34+ CPCs with capacity for homing and tissue repair. 12 The bone marrow is a major reservoir for PCs where they are maintained in quiescent state. We and others have shown that CPC numbers and activity are modulated by age, sex, presence of CVD risk factors, and subclinical and clinical CVD. [13] [14] [15] [16] [17] [18] [19] The hemostasis of the PCs in bone marrow niches is regulated by signaling pathways that include cytokines, chemokines, and inflammatory factors. Under specific conditions such as acute myocardial infarction (AMI), PC-mobilizing factors such as SDF-1α (stromal cell-derived factor-1α), VEGF, and MMP-9 (matrix metallopeptidase-9) permit PC release from their bone marrow niches, and their subsequent proliferation, differentiation, and mobilization into the circulation. 15, 20, 21 Furthermore, chemokines such as MCPs (monocyte chemoattractant proteins) regulate trafficking of leukocytes to sites of inflammation and injury. It remains unknown if there are racial differences in PC mobilization or PC-signaling pathways.
Finally, we and others have demonstrated that impaired regenerative capacity, estimated as reduced levels of CPCs independently predicts outcomes in patients with coronary artery disease (CAD), acute coronary syndromes, peripheral artery disease, heart failure, stroke, and other conditions. [15] [16] [17] [18] Whether differences in endogenous regenerative capacity contributes to the racial disparities of CVD remains unknown and is the focus of this investigation. Herein, we hypothesized that compared with whites, blacks will have (1) significantly lower level of CPCs; (2) diminished mobilization of PCs in the setting of AMI; (3) differences in circulating levels of PC-mobilizing factors; and (4) similar predictive value of low CPC levels for adverse outcomes.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design and Subjects
We identified adults from a database that included patients recruited into the Emory Cardiovascular Biobank, a prospective registry of patients undergoing cardiac catheterization, from the Mental Stress Ischemia Prognosis Study, a prospective study that recruited patients with stable CAD, and Emory Predictive Health Initiative, a study that recruited employees of Emory University and Georgia Institute of Technology without overt CVD, as previously described. [22] [23] [24] We excluded subjects who had cardiac transplantation, cancer or were on immunosuppressive agents. Race was self-reported, and other
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Novelty and Significance
What Is Known?
• Impaired regenerative capacity, measured as low circulating levels of progenitor cells, is associated with adverse clinical outcomes.
• Progenitor cells are mobilized from the bone marrow into the circulation in response to ischemia and home to ischemic tissue, thereby contributing to repair and regeneration.
• In comparison with whites, blacks have higher cardiovascular risk and worse outcomes, but little is known about racial differences in circulating numbers of progenitor cells.
What New Information Does This Article Contribute?
• Compared with whites, blacks had lower numbers of circulating progenitor cells and diminished mobilization during acute myocardial injury.
• Lower levels of progenitor cells in blacks are partially dependent on lower circulating MMP-9 (matrix metallopeptidase-9) levels.
• Low circulating progenitor cell counts are predictive of higher mortality in blacks. Thus, reduced regenerative capacity may partly explain the higher risk of adverse cardiovascular events in blacks.
Progenitor cells originate from the bone marrow and contribute to tissue repair and regeneration. Compared with white subjects, blacks with or without cardiovascular disease or risk factors have significantly lower circulating levels of hematopoietic and endothelial progenitor cells. Decreased regenerative capacity in blacks measured as lower levels of circulating progenitor cells can be partially explained by lower levels of circulating MMP-9 levels in blacks. Lower circulating progenitor cell levels are independently associated with a higher mortality rate in blacks. Therapeutic interventions to enhance progenitor cell levels may represent a novel therapeutic target for reducing health disparities.
non-white racial groups were excluded for the purpose of this analysis. Demographic characteristics, medical history, medication use, and behavioral habits were documented as previously described. 22, 25 At the time of enrollment, CPCs were measured from peripheral blood samples. Subjects presenting with AMI were analyzed separately. AMI was diagnosed according to the American College of Cardiology/ American Heart Association guidelines by the presence of selfreported chest pain and evidence of cardiac ischemia on 12-lead electrocardiogram or elevated cardiac enzymes greater than twice the upper limit of normal with angiographic findings consistent with AMI diagnosis. The study was approved at Emory University (Atlanta, GA) by the Institutional Review Board. All participants provided written informed consent.
Validation Cohort
To validate the association between CPCs and black race, we performed a separate analysis in an independent cohort of 411 subjects (16% black) enrolled between 2006 and 2008 at Emory University affiliated hospitals. Both cohorts were enrolled under the same protocol, with identical sampling strategies and collection methods but separated in time and by a modified cell quantification methodology.
Progenitor Cells Assays
Peripheral blood was collected in EDTA tubes and incubated with fluorochrome-labeled monoclonal antihuman mouse antibodies within 4 hours. Cell populations enriched for CPCs were enumerated using flow cytometry as CD45dim cells coexpressing CD34+, CD133+, VEGFR2+, or CXCR4+. CD34+/CD45med+ represent 95% of the total CD34+; CD34+/CD133+/CD45med+ represent 98% of CD34+/CD133+; CD34+/CXCR4+/CD45med+ represent 94% of CD34+/CXCR4+; and CD34+/VEGF+/CD45med represent 64% of CD34+/VEGF. This selection of CD45med helps eliminate a subset of other progenitors like mesenchymal or osteoprogenitor cells as these are typically CD45neg. 26 Moreover, eliminating the rare CD45bright CD34+ cells helps eliminate hematogones (early B-cell precursors). We incubated 300 μL of peripheral blood with 7 μL of FITC-CD34 (BD Biosciences), PerCP-CD45 (BD Biosciences), PE-VEGFR2 (R&D system), and 5 μL APC-CD133 (Miltenyi), and 3 μL PE-Cy7-conjugated anti-CXCR4 (EBioscience, clone 12G5) in the dark for 15 minutes. 27 Then 1.5 mL ammonium chloride lysing buffer was added to lyse red blood cells. Staining medium (1.5 mL; PBS with 3% heat-inactivated serum and 0.1% sodium azide) was added to stop the lysing reaction. Before flow cytometry, 100 μL of AccuCheck Counting Beads (Invitrogen, Cat number: PCB100) were added to act as an internal standard for direct estimation of the concentration of target cell subsets. At least 2.5 million events were acquired from the cytometer. Flow data were analyzed with Flowjo software (Treestar, Inc). Absolute mononuclear cell count was estimated as the sum of lymphocytes and monocytes using a Coulter ACT/Diff cell counter (Beckman Coulter). Progenitor cells populations are reported as cell counts/mL. In 20 samples that were repeatedly analyzed on 2 occasions by the same technician, the coefficients of variation of the cell types were CD34+2.9%, CD34+/CD133+4.8%, CD34+/CXCR4+6.5% and CD34+/CD133+/ CXCR4+7.5%, CD34+/VEGFR2+ cells 21.6%. There were significant correlations between the progenitor cells subtypes, with moderate-strong correlations between CD34+, CD34+/CD133+, CD34+/ CXCR4+ (r range, 0.82-0.91; P<0.001), and weak correlations (r range, 0.08-0.29; P<0.001) between CD34+/VEGFR2+ subtypes and the aforementioned progenitor cells. In the validation cohort, similar methods were used to enumerate CPCs (CD34+ and CD34+/ CD133+) but without the addition AccuCheck Counting Beads or PE-Cy7-conjugated anti-CXCR4.
Biomarker Measurements
Biomarkers were measured in 561 subjects enrolled in the Mental Stress Ischemia study including hs-CRP (high-sensitivity C-reactive protein), SDF-1α, VEGF, MMP-9, and MCP-1. We used high-sensitivity assays using the MesoScale system (Meso Scale Diagnostics Rockville, MD) using the SECTOR Imager 2400 to quantify hs-CRP, SDF-1α, VEGF, MMP-9, and MCP-1 according to the protocols supplied by the manufacturer. The Mesoscale multiplex assay system uses electrochemiluminescence for high-sensitivity and broad Data presented as n (%) and mean±SD. Progenitor cells and biomarkers counts are presented as median (interquartile range). ACE/ARB indicates angiotensinconverting enzyme inhibitors/angiotensin receptor blockers; CABG, coronary artery bypass surgery; GFR, glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein-1; MMP-9, matrix metallopeptidase-9; PCI, percutaneous coronary intervention; SDF-1α, stromal cell-derived factor-1α; and VEGF, vascular endothelial growth factor. dynamic range. Lower limits of detection for our experiment were hs-CRP, 1.33 × 10−6 mg/L; SDF-1α, 27.8 pg/mL; VEGF, 1.12 pg/mL; MMP-9, 0.011 ng/mL; and MCP-1, 0.09 pg/mL. The interassay coefficient of variations for midpoint standards were 3.79% for SDF-1α, 4.26% for VEGF, 9.38% for MMP-9, and 4.99% for MCP-1. The intra-assay coefficients of variations were 2.33% for hs-CRP; 3.45% for MCP-1, and 5.95% for MMP-9.
Follow-Up and Outcomes
Patients enrolled in the Emory Cardiovascular Biobank were followed for determination of the primary outcome of all-cause death obtained by phone contact, electronic medical record review, and data from the social security death index and state records. Adjudication was conducted by personnel blinded to the data. Baseline characteristics for follow-up cohort are shown in Table I in the Online Data Supplement.
Statistical Analysis
Subject characteristics were reported as descriptive statistics with means, medians, SDs, and ranges. Differences between groups were assessed using the t test for continuous variables, and χ 2 or Fischer exact tests for categorical variables where appropriate. Spearman rank correlation coefficients were used for examining associations between PCs and continuous variables. Two-sided P value of <0.05 was considered statistically significant. For non-normally distributed variables such as CPC counts and biomarkers, Mann-Whitney U test was used to compare groups in unadjusted analyses. For multivariable analyses, PCs counts were examined as continuous variables after log-transformation to achieve normality. Characteristics incorporated in multivariable analyses included age, sex, race (white versus black), body mass index, hypertension, hyperlipidemia, diabetes mellitus, estimated glomerular filtration rate, history of CAD, history of heart failure. Analyses were repeated in the validation cohort after adjusting for the same variables. The association between CPC counts and outcomes was examined in Kaplan-Meier and Cox regression models. We analyzed CPC counts as a continuous variable after log-transformation and as binary variables using a prespecified cutoff that were previously shown to be predictive of worse prognosis (737 cells/mL for CD34+ subset). 26 Analyses were performed using IBM SPSS Statistics Version 23 (Armonk, NY).
Results
Of the 1747 subjects enrolled aged 59±13 years, 457 (26%) were black. Compared with whites, black subjects were younger, less likely to be male, with a higher body mass index and were more likely to smoke, have hypertension, diabetes mellitus, and heart failure ( Table 1) .
Race and CPC Counts
In unadjusted analyses, both CD34+ and CD34+/CXCR4+ cell counts were lower in blacks compared with whites. After multivariable adjustment for age, race, smoking history, body mass index, hypertension, diabetes mellitus, dyslipidemia, estimated glomerular filtration rate, heart failure, CAD, and mononuclear cell counts, black race was an independent determinant of CPC counts and was associated with fewer CD34+ cells (−17.6%; [95% confidence interval (CI), −23.52% to −11.25%]; P<0.001), CD34+/CD133+ cells (−15.52%; [95% Table 2 ).
Validation Analysis
The racial differences in the CPC subsets between white and black subjects were validated in an independent cohort of 411 subjects (mean age 63.0±11, 63% male, and 16% black). Baseline characteristics are shown in 
Racial Differences in CPCs and Interactions With Demographic and Risk Factor Characteristics
There was a decline in CPCs with age and men had higher CPC counts compared with women as previously reported. 25 Blacks had lower CPC levels at all ages (Figure 1 ), and black women had lower CPC counts compared with black men (15.26% fewer CD34+ cells (95% CI, 0.2%, 32.45%; P=0.04). Thus, CPC counts in whites were similar to blacks who were on average 14 years younger. There were no significant interactions between lower CPC counts in blacks compared with whites and either age, sex, or the individual risk factors including diabetes mellitus, hypertension, hyperlipidemia, chronic kidney disease, or presence of CVD (CAD, heart failure, or peripheral arterial disease; P for interaction >0.1 for all; Figure 2 ).
To ensure that the differences we observed in the entire population were not because of the overall increased risk factor burden in blacks, we investigated racial differences in CPCs in a subset of patients (n=343) 
Racial Differences in CPCs in Patients With AMI
Baseline characteristics of 91 patients admitted with an AMI (30% black, 45 with ST-segment-elevation myocardial infarction) are shown in Table 4 . We measured CPCs at the time of the angiogram which is typically done within 24 after presentation with an AMI. CPC counts were higher in those with AMI compared with stable CAD patients even after adjustment for clinical risk factors, as previously shown. 15 Black subjects had significantly lower CD34+ counts compared with whites ( 
Racial Differences in Circulating Biomarkers and Their Relationship With CPCs
In 561 subjects, blacks compared with whites had higher levels of hs-CRP and MCP-1, and lower levels of MMP-9. However, circulating VEGF and SDF-1α levels were not significantly different between the races (Tables 1 and 3) . In adjusted analyses, MCP-1 correlated negatively with CPCs, whereas MMP-9 levels correlated positively with CPC counts (Figure 3) . SDF-1α, hs-CRP, or VEGF levels were not independent predictors of CPCs (Table 5) . Thus, MMP-9 levels (log) were independently associated with 30.25% higher CD34+ count (95% CI, 18.5%-43.17%; P<0.001).
In multivariable analysis, the association between CPCs and black race was attenuated by adding MMP-9 levels to the model. Thus, there was 19% (95% CI, 13%-33%) Figure 1 . Age-related decline in circulating progenitor cell counts among black and white subjects. P values are derived from adjusted linear regression models. attenuation for the association between black race and CD34+ cells, 18% (95% CI, 12%-35%) for CD34+/CD133+ cells and 17% (95% CI, 10%-40%) for CD34+/CXCR4+ cells. However, black race remained a significant predictor for lower numbers of CPCs without significant attenuation after additional adjustment for serum hs-CRP, VEGF, SDF-1α, or MCP-1 levels.
CPCs and Prognosis
Among 623 patients with a median follow-up of 2.2 (IQR, 1.3-4.5) years, there were 108 deaths (17%) from all causes. We also analyzed survival based on a prespecified cutoff that were previously shown to be predictive of worse prognosis (737 cells/mL for CD34+ subset). 16, 25 In the entire cohort, CD34+ cells were also predictive of all-cause mortality (adjusted HR=1.91; [95% CI, 1.21-3.00]; P=0.005) based on this cutoff value. Similarly, CD34+ levels below median was associated with HR=1.53 (95% CI, 1.04-2.27; P=0.03). Black subjects had a 2-fold higher adjusted odds of having CD34+ cells below the prespecified cutoff (737 cells/mL). Moreover, using stepwise backwards Cox regression model with P<0.1 as the threshold to retain a variable, a low CD34+ cell count (<737 cells/mL) was similarly predictive of survival in blacks (adjusted HR=2.83; [95% CI, 1.12-7.20]; P=0.03) and whites (adjusted HR=1.79; [95% CI, 1.09-2.94]; P=0.02) with nonsignificant interaction (P>0.2; Figure 4 ).
Discussion
In a large well-characterized biracial cohort, we demonstrate that black participants had significantly lower CPC counts compared with whites, even after adjustment for differences in demographic factors and CVD risk factors. These results were validated in an independent cohort. Thus, on average, after adjustment for sex and other CVD risk factors, blacks have CPC levels that are ≈15% to 30% lower compared with whites, even in subjects free of risk factors. CPC levels decline with age, reaching on average half the levels at age 80 compared with age 20. 25 We found that blacks have CPC counts equivalent to those in whites who are 14 years older. CPC levels are higher after AMI as a result of mobilization because of injury. 15 We show for first time that blacks have 30% to 35% lower CPC mobilization in the setting of AMI.
We also investigated whether the racial differences in CPCs were driven by differences in inflammation, chemokine, or cytokine signaling pathways previously associated with PC mobilization. Our results demonstrate that although levels of MMP-9 were lower and MCP-1 were higher in blacks compared with whites, only the lower levels of MMP-9 levels in Data presented as n (%) and mean±SD. Progenitor cells and troponin levels are presented as median (interquartile range). AMI indicates acute myocardial infarction; CABG, coronary artery bypass surgery; GFR, glomerular filtration rate; and PCI, percutaneous coronary intervention. blacks, at least partly, contribute to the lower levels of CPCs. To explore whether there are any adverse consequences of low PC counts in blacks compared with whites, we examined the prognostic value of CPCs in patients with CAD. Our data show that low CPC counts were similarly associated with a higher mortality in both racial groups. Because blacks have lower CPC counts, this reduced endogenous regenerative capacity may be one additional reason for the observed disparities in CVD outcomes between blacks and whites.
Racial differences in CPCs have not been systematically investigated previously. One study reported similar CD34+/ VEGF2R+ cell levels in 36 white and black hypertensive subjects, 28 findings that may be explained by the small sample size and lack of structured multivariable adjustment for confounders.
In response to endogenous and exogenous stimuli, increased production of PC-mobilizing factors (such as hypoxia-inducible factor activation, VEGF, and SDF-1α) increase levels of PCs. 21 Mechanisms contributing to cytokine-induced PC mobilization include cytokine gradients, cellular proliferation, modulation of adhesion molecules, and modulation of the blood-bone marrow barrier. 29, 30 These factors also activate endothelial nitric oxide synthase, leading to an increased production of nitric oxide, which regulates the enzymatic activity of MMPs. 21 In particular, activated MMP-9 leads to the release of a soluble kit ligand from PCs in the bone marrow niches, resulting in PC release into the peripheral circulation. 20, 31 Availability of nitric oxide is important in PC mobilization and function that may also be impaired in blacks. 32, 33 Both VEGF and SDF-1α stimulate PC mobilization from the bone marrow and regulate their angiogenic properties and their levels correlated with CPC levels in our study. 21 However, VEGF and SDF-1α levels did not differ between black and white subjects and the association between lower CPCs and black race was still significant after adding their levels to the model. In contrast, we found that MMP-9 levels correlated positively with CPC levels, its' level was lower in blacks, and accounted for 19% of the racial variability observed in CPC counts. 32 It is known that monocyte and PC mobilization from bone marrow niches requires stimulation of chemokine receptors by the activity of MMP-9. 20, 33 Our findings demonstrate that lower MMP-9 activity in blacks contributes, at least partly, to the reduced levels of CPCs in blacks.
Studies using cord blood have shown that blacks had significantly lower PC counts than other racial/ethnic groups, indicating that the racial differences in CPCs that we observed may be present even at birth and illustrate the importance of a potential genetic basis for the observed differences. 34 The Framingham Heart Study demonstrated that CD34+ PC frequency was highly heritable and polymorphisms in several loci, including OR4C12, ENO1/RERE, DGKB, and DSC3 correlated with CD34+ cell counts. 35 Additional variants in the MPL gene that regulates platelet and megakaryocyte receptors for thrombopoietin seem to regulate PCs in the bone marrow niche. 36 Further evaluation of race-associated genetic polymorphisms and CPC levels may help identify the potential genetic mechanisms underlying the impaired regenerative capacity in blacks.
We also found that blacks had ≈30% to 35% lower hematopoietic-enriched CPC counts in the setting of large AMI compared with whites. These findings suggest that not only do blacks have lower CPC levels, but their ability to mobilize in response to injury is impaired. Previous studies have also reported that blacks mobilize greater numbers of CD34+ PCs compared with whites after granulocyte colony-stimulating factor administration, suggesting that even though their response to endogenous stimuli is impaired, the response to exogenous mobilization agent (granulocyte colony-stimulating factor) is in fact greater. 37, 38 Our data did not show significant racial differences in hematopoietic-enriched CPCs in the setting of AMI which could be explained by their very low frequency and poor reproducibility compared with the more frequent hematopoietic-enriched CPC subsets.
To evaluate the long-term consequences of lower CPC counts among blacks, we assessed the prognostic value of CPCs in a population with CAD. Our study is the first to report the strong predictive value of CPCs in blacks. We also found that the increased risk associated with lower CPC counts is similar among blacks and whites. Thus, the lower regenerative capacity puts black subjects at added risk, over and above their risk factor burden, for worse CVD outcomes. These are novel and consequential findings that partly explain the increased CVD risk in blacks and strategies to address regenerative capacity need to be further explored.
Strengths of our study include (1) a large study of >2300 subjects which allowed comparison of CPC counts across several groups with and without a variety of CVD phenotypes; (2) the use of state-of-the-art flow cytometry for quantification of CPCs by the same technical team 27 ; (3) inclusion of subjects with and without risk factors, with and without CVD, and in the setting of acute MI; (4) exploration of a wide selection of CD34+ cell subpopulations encompassing hematopoietic and endothelial progenitors; (5) exploring the effect of inflammatory cytokines and chemokines on the association between race and CPCs; and (6) long-term follow-up for mortality. Limitations of our study include (1) the determination of race by self-report that potentially introduces bias in individuals with mixed ancestry; (2) lack of comparison with other races; (3) lack of information on sickle cell trait that is more common in blacks and could potentially have confounded our findings, although we and others have shown previously that patients with sickle cell disease have higher CPC counts 39, 40 ; (4) absence of functional measurements of CPCs; (5) single measurement at varying time points after the AMI; and (6) our study recruited patients from Emory healthcare system and thus, the results might not be generalizable to other patient cohorts or other geographic regions.
In conclusion, this is the first study to demonstrate lower CPC counts in blacks compared with whites in a large cohort of subjects with and without cardiovascular risk factors and CVD which is partially dependent on lower MMP-9 levels in blacks. Blacks also have reduced CPC mobilization in the setting of an AMI. These findings demonstrate that blacks have impaired regenerative capacity compared with whites, independent of their risk factor profile or biomarkers of chemotaxis. Because lower CPC counts are associated with worse long-term outcomes, these findings may explain the racial disparities in outcomes. Further studies are required to examine genetic and other mechanisms contributing to these disparities and discuss potential targets for new interventions and research priorities. 
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